The Executive Yuan yesterday approved two bills to govern regenerative medicine that aim to boost development of the field.
Taiwan would reach an important milestone in regenerative medicine development with passage of the regenerative medicine act and the regenerative medicine preparations ordinance, which would allow studies to proceed and treatments to be developed, Deputy Minister of Health and Welfare Victor Wang (王必勝) told reporters at a news conference after a Cabinet meeting.
Regenerative treatments have been used for several conditions, including cancer — by regenerating blood cells — and restoring joint function in soft tissue, Wang said.
Photo: Taipei Times
The draft legislation requires regenerative treatments to undergo human trials, he said.
“However, human trials might be waived if patients’ lives are in danger or in other extenuating circumstances,” he added.
Ministry of Health and Welfare Department of Civil Ethics Director-General Liu Yueh-ping (劉越萍) said that waivers for human trials would only be granted when people seek new treatments after other methods have failed.
The draft regenerative medicine bill stipulates that only government-certified medical institutions can administer such treatments, with individuals or organizations that administer them without permission to face fines of NT$2 million to NT$20 million (US$61,391 to US$613,911).
Non-medical institutions would face fines of NT$2 million to NT$20 million for advertising for the use of regenerative medical treatments, the bill says.
The bill also lists the conditions under which medical institutions could proceed with regenerative medical treatments without first conducting human trials.
People must have a life-threatening or severely debilitating disease, and Taiwan cannot have medication, equipment or technology that meets the need, while medical institutions can offer regenerative medical treatments that have been approved by the ministry before the bill is promulgated, it says.
The bill would also upgrade the status of the Ethical Guidelines Governing the Research of Human Embryos and Embryonic Stem Cell Research to law. The guidelines state that embryos and embryonic stem cells used in regenerative medical studies must not be produced through artificial insemination.
Moreover, embryos or embryonic stem cells acquired for research cannot be used to implant nucleated human ova in cell nuclei of other species, the guidelines say.
Researchers would be banned from acquiring research-use embryos for embryonic stem cells or using them to produce chimeric species that have human germ cells, the guidelines say.
The regenerative medicine preparations ordinance covers treatments that contain genes, cells and their derivatives for human use, including gene therapy, cell therapy and tissue engineering.
Pharmaceutical firms seeking to manufacture or import regenerative treatments must have their facilities inspected and registered, and they must be approved and issued a valid license to manufacture or import the products, the bill says.
Licenses would be valid for five years and can be extended for another five years if an extension is applied for three to six months in advanced and it is approved, the bill says.
To facilitate “compassionate treatment” for people with life-threatening illnesses for which other treatments are not available, the bill authorizes the ministry to approve under certain conditions the use of regenerative products after a phase 2 clinical trial has been completed and the product has been shown to be safe and effective.
Licenses for such products would be valid for five years and cannot be extended.
Both bills have regulations to protect people seeking regenerative treatment or medication.
The ministry has the authority to stop or terminate all or part of a regenerative treatments if a medical provider is facing an unusually high number of liability cases.
TRAFFIC SAFETY RULES: A positive result in a drug test would result in a two-year license suspension for the driver and vehicle, and a fine of up to NT$180,000 The Ministry of Transportation and Communications is to authorize police to conduct roadside saliva tests by the end of the year to deter people from driving while under the influence of narcotics, it said yesterday. The ministry last month unveiled a draft of amended regulations governing traffic safety rules and penalties, which included provisions empowering police to conduct mandatory saliva tests on drivers. While currently rules authorize police to use oral fluid testing kits for signs of drug use, they do not establish penalties for noncompliance or operating procedures for officers to follow, the ministry said. The proposed changes to the regulations require
Taipei, New Taipei City, Keelung and Taoyuan would issue a decision at 8pm on whether to cancel work and school tomorrow due to forecasted heavy rain, Keelung Mayor Hsieh Kuo-liang (謝國樑) said today. Hsieh told reporters that absent some pressing reason, the four northern cities would announce the decision jointly at 8pm. Keelung is expected to receive between 300mm and 490mm of rain in the period from 2pm today through 2pm tomorrow, Central Weather Administration data showed. Keelung City Government regulations stipulate that school and work can be canceled if rain totals in mountainous or low-elevation areas are forecast to exceed 350mm in
The Executive Yuan yesterday announced that registration for a one-time universal NT$10,000 cash handout to help people in Taiwan survive US tariffs and inflation would start on Nov. 5, with payouts available as early as Nov. 12. Who is eligible for the handout? Registered Taiwanese nationals are eligible, including those born in Taiwan before April 30 next year with a birth certificate. Non-registered nationals with residence permits, foreign permanent residents and foreign spouses of Taiwanese citizens with residence permits also qualify for the handouts. For people who meet the eligibility requirements, but passed away between yesterday and April 30 next year, surviving family members
1.4nm WAFERS: While TSMC is gearing up to expand its overseas production, it would also continue to invest in Taiwan, company chairman and CEO C.C. Wei said Taiwan Semiconductor Manufacturing Co (TSMC) has applied for permission to construct a new plant in the Central Taiwan Science Park (中部科學園區), which it would use for the production of new high-speed wafers, the National Science and Technology Council said yesterday. The council, which supervises three major science parks in Taiwan, confirmed that the Central Taiwan Science Park Bureau had received an application on Friday from TSMC, the world’s largest contract chipmaker, to commence work on the new A14 fab. A14 technology, a 1.4 nanometer (nm) process, is designed to drive artificial intelligence transformation by enabling faster computing and greater power
RSS